NGM707 clinical trials

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

This study is looking at a new drug, NGM707, alone and with an existing drug, pembrolizumab, for certain advanced cancers. Doctors want to see how safe the drugs are and if they can shrink tumors.